Brown & Brown (BRO) is back in focus after reporting second quarter 2026 results that show higher revenue and net income compared with a year earlier, drawing fresh attention to the stock’s recent performance.

Brown & Brown’s recent earnings, active buybacks and affirmed dividend have come alongside a 26.91% 90-day share price return but a 21% decline in 1-year total shareholder return. This indicates that recent momentum is rebuilding from a weaker longer-term backdrop.

If you are weighing Brown & Brown’s mix of acquisitions and capital returns, it can help to broaden your search and check out 19 top founder-led companies

The recent rebound in Brown & Brown shares sits against a 40% intrinsic discount estimate and a smaller gap to the consensus price target. So where does fair value really land as the market reassesses this stock?

Most Popular Narrative: 5.1% Undervalued

Brown & Brown's most followed valuation narrative points to a fair value of about $75.63, which sits modestly above the last close at $71.78. That gap is small enough that the details behind the forecast matter more than the headline number.

Strong cash flow from operations, combined with a strategic focus on leveraging a diversified portfolio across geographies and lines of business, positions the company to navigate economic uncertainties and potentially increase future earnings stability and growth.

Curious what sits behind that fair value for Brown & Brown? The narrative leans on measured revenue growth, slightly leaner margins, and a richer future earnings multiple. The exact mix of those inputs may surprise you.

Result: Fair Value of $75.63 (UNDERVALUED)

However, Brown & Brown’s story can change quickly if tariff or interest rate shocks slow client activity, or if rising pharmacy costs squeeze employee benefits margins.

Another View On Brown & Brown’s Valuation

While the most followed narrative puts Brown & Brown at about 5.1% undervalued using a fair value of $75.63, the current P/E of 20.2x tells a different story. It is higher than both the US Insurance industry at 11.9x and the fair ratio of 13.3x, yet lower than peers at 33.5x. That mix hints at both valuation risk if sentiment cools and potential support if the market keeps rewarding the peer group, so which side do you think dominates?

Next Steps

With sentiment on Brown & Brown split between valuation questions and fundamentals, it makes sense to move quickly and test the data yourself. A useful place to start is by getting a clear view of both sides of the story through 2 key rewards and 2 important warning signs

Looking for more investment ideas beyond Brown & Brown?

If you stop with Brown & Brown, you might miss other stocks that fit your goals. Take a few minutes to scan fresh ideas that match your style.

• Target potential mispricing by reviewing companies that appear overlooked on quality and valuation through the 53 high quality undervalued stocks.
• Strengthen your income focus by checking stocks that feature reliable cash distributions via the 7 dividend fortresses.
• Cushion portfolio risk by scanning companies that score well on resilience through the 82 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.